Soligenix, a development-stage biopharmaceutical company, has collaborated with the Infectious Disease Research Institute (IDRI) to develop select biodefense vaccines using synthetic adjuvants.
The collaboration will leverage IDRI's synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform, known as ThermoVax.
IDRI adjuvant technology vice president, Darrick Carter, said that IDRI's adjuvant technology can help build effective vaccines.
"These new candidate vaccines could be the critical solution in providing protection to people in the event there is a bioterror threat from the release of anthrax or ricin toxins," Carter added.
The combination of the technologies is expected to result in vaccines with characteristics for long-term stability and onset of protective immunity, desired features of vaccines that would be stockpiled for emergency use.
The collaboration initially aims at evaluating the combination of one of IDRI's adjuvant compounds that has been shown to enhance the generation of high-titer neutralising antibodies to anthrax toxin with VeloThrax, Soligenix's second generation Dominant Negative Inhibitor subunit protein anthrax vaccine candidate.
The second developmental objective is to appraise the combination of an IDRI adjuvant with formulations of RiVax, Soligenix's vaccine against ricin toxin under development.
The research will initially be conducted under Soligenix's existing $9.4m National Institute of Allergy and Infectious Disease grant, which supports the development of advanced heat stable vaccines against anthrax and ricin toxins.
Soligenix president and CEO Christopher Schaber said: "We believe that with the addition of IDRI's potent adjuvants to our hyperimmunogenic anthrax and ricin toxin vaccines, we will have the potential to develop highly competitive biodefense vaccines that can address the exact needs of the US government with regard to rapid onset immunity with just one or two doses."